Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...
Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...
...